Posted 02 August, 2023
Optimus Healthcare Services, Inc. appointed Cliff Saffron as new CEO
OTC:OHCS appointed new Chief Executive Officer Cliff Saffron in a 8-K filed on 02 August, 2023.
On July 27, 2023, Cliff Saffron, the current Chief Operating Officer and General Counsel of the Company, was appointed as the President and Interim Chief Executive Officer of the Company.
Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Optimus Healthcare Services, Inc.
Retail/Wholesale • Specialty Retail
Optimus Healthcare Services, Inc. is focused on creating a network of innovative healthcare companies that advance clinical research, disease management, and improve physician or patient interactions. It is engaged in acquiring controlling interest of healthcare-related businesses with its products, services and technologies or processes that access to healthcare and improve overall health outcomes and physical well-being. The firm's portfolio of companies include PainScript, Clinical Research Alliance, and VaccinationsRx. The company was founded by Sean Spiegelman on February 26, 1990 and is headquartered in Westbury, NY.Market Cap
$5.40M
View Company Details
$5.40M
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 27, 2023, Optimus Healthcare Services, Inc. (the "Company"), terminated John Sganga as chief executive officer and all other officer positions, effective immediately. Mr. Sganga was terminated for cause and will not receive any severance payments under his employment agreement with the Company. On July 27, 2023, Cliff Saffron, the current Chief Operating Officer and General Counsel of the Company, was appointed as the President and Interim Chief Executive Officer of the Company. On July 10, 2023, Mr. Saffron was also appointed as Chief Operating Officer of the Company. Mr. Saffron has served as General Counsel of the Company since May 2021. There are no arrangements or understandings between Mr. Saffron and any other person pursuant to which Mr. Saffron was appointed to serve as the Interim Chief Executive Officer of the Company. There are no family relationships between Mr. Saffron and any of the Company's directors or executive officers. Mr. Saffron has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K. Mr. Saffron is party to an Employment Agreement with the Company (the "Agreement"), which took effect on May 25, 2021, as subsequently amended on August 25, 2022. Mr. Saffron's base salary is $214,000 per year and he is eligible to receive an annual bonus of up to 50% of his base salary per year at the discretion of the Board. Mr. Saffron was also granted options to purchase 250,000 shares of our common stock on May 25, 2021 at an exercise price of $1.80 per share, and on January 14, 2022, options to purchase 40,000 shares of our common stock at an exercise price of $1.85 per share. Both stock option grants vest in four equal installments commencing on the date of the grant and each anniversary thereafter. Mr. Saffron is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with our policies established and in effect from time to time. The agreement may be terminated by the Company at any time and for any reason (or no reason), and with or without cause, provided if the agreement is terminated without cause, the Company is required to provide Mr. Saffron at least 1-day prior written notice. Mr. Saffron may terminate the agreement for any reason (or no reason) upon 30 days prior written notice. If the employment agreement is terminated by the Company without cause or if Mr. Saffron terminates his employment for good reason, Mr. Saffron shall receive: (i) a pro-rated bonus for the year in which such termination became effective: (ii) continued payment of his base compensation during the 12 month period following termination; (iii) immediate vesting of all unvested equity awards held immediately prior to his termination date; and (iv) payment of the cost of medical insurance for a period of 12 months following termination. The employment agreement also contains covenants: (i) assigning all intellectual property developed by Mr. Saffron during the employment term to us; (ii) prohibiting the executive from disclosing confidential information regarding us; and (iii) from soliciting our employees or consultants during the term of the employment agreement and for a period of one year thereafter. - 1 -
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.